![Bernhard Eggimann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernhard Eggimann
Corporate Officer/Principal presso Enobia Pharma, Inc.
Posizioni attive di Bernhard Eggimann
Società | Posizione | Inizio | Fine |
---|---|---|---|
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 09/12/2010 | - |
Storia della carriera di Bernhard Eggimann
Statistiche
Distribuzione geografica
Canada | 2 |
Posizioni
Corporate Officer/Principal | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Borsa valori
- Insiders
- Bernhard Eggimann
- Esperienza